Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com

Loading...
Loading...

RnRMarketResearch.com adds “Pulmonary Fibrosis – Pipeline Review, H1 2015” to its store. The report provides an overview of the Pulmonary Fibrosis's therapeutic pipeline.

Dallas, TX (PRWEB) January 26, 2015

The report "Pulmonary Fibrosis – Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fibrosis-pipeline-review-h1-2015-market-report.html .

It also reviews key players involved in the therapeutic development for Pulmonary Fibrosis and special features on late-stage and discontinued projects. Companies discussed in this Pulmonary Fibrosis Pipeline Review H1 2015 report include AdAlta Pty Ltd., Aeolus Pharmaceuticals, Inc., AnaptysBio, Inc., Angion Biomedica Corp., Aquinox Pharmaceuticals Inc., Auspex Pharmaceuticals, Inc., Biogen Idec Inc., BiOrion Technologies B.V., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Carolus Therapeutics, Inc., Celgene Corporation, Chong Kun Dang Pharmaceutical Corp., Compugen Ltd., Corridor Pharmaceuticals Inc., Digna Biotech, S.L., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., FibroGen, Inc., Five Prime Therapeutics, Inc., Galectin Therapeutics, Inc., GenKyoTex S.A., Gilead Sciences, Inc., GlaxoSmithKline plc, HanAll Biopharma Co., Ltd., Histocell S.L., iBio, Inc., IMMD Inc., ImmuneWorks, LLC, IntelGenx Corp., InterMune, Inc., Inventiva SAS, Kasiak Research Pvt. Ltd., Kyorin Pharmaceutical Co., Ltd., Lanthio Pharma B.V., Lpath, Inc., LTT Bio-Pharma Co., Ltd., MedImmune, LLC, Mesoblast Limited, miRagen Therapeutics, Inc., Moerae Matrix, Inc., MSM Protein Technologies, Inc., NicOx S.A., Pacific Therapeutics Ltd., Pharmaxis Limited, Pluristem Therapeutics Inc., Progenra, Inc., Promedior, Inc., ProMetic Life Sciences Inc., Pulmatrix, Inc., RestorGenex Corporation, Rhizen Pharmaceuticals SA, Sanofi, Therametrics holding AG, Vectura Group plc.

The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Order a Purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=269511 . (This is a premium report priced at US$2000 for a single user License.)

Table of Contents

List of Tables
Number of Products under Development for Pulmonary Fibrosis, H1 2015 18
Number of Products under Development for Pulmonary Fibrosis - Comparative Analysis, H1 2015 19
Number of Products under Development by Companies, H1 2015 21
Number of Products under Development by Companies, H1 2015 (Contd..1) 22
Number of Products under Development by Companies, H1 2015 (Contd..2) 23
Number of Products under Development by Companies, H1 2015 (Contd..3) 24
Number of Products under Development by Companies, H1 2015 (Contd..4) 25
Number of Products under Investigation by Universities/Institutes, H1 2015 26
Comparative Analysis by Late Stage Development, H1 2015 27
Comparative Analysis by Clinical Stage Development, H1 2015 28
Comparative Analysis by Early Stage Development, H1 2015 29
Comparative Analysis by Unknown Stage Development, H1 2015 30
Products under Development by Companies, H1 2015 31
Products under Development by Companies, H1 2015 (Contd..1) 32
Products under Development by Companies, H1 2015 (Contd..2) 33
Products under Development by Companies, H1 2015 (Contd..3) 34
Products under Development by Companies, H1 2015 (Contd..4) 35
Products under Development by Companies, H1 2015 (Contd..5) 36
Products under Investigation by Universities/Institutes, H1 2015 37
Pulmonary Fibrosis - Pipeline by AdAlta Pty Ltd., H1 2015 38
Pulmonary Fibrosis - Pipeline by Aeolus Pharmaceuticals, Inc., H1 2015 39
Pulmonary Fibrosis - Pipeline by AnaptysBio, Inc., H1 2015 40
Pulmonary Fibrosis - Pipeline by Angion Biomedica Corp., H1 2015 41
Pulmonary Fibrosis - Pipeline by Aquinox Pharmaceuticals Inc., H1 2015 42
Pulmonary Fibrosis - Pipeline by Auspex Pharmaceuticals, Inc., H1 2015 43
Pulmonary Fibrosis - Pipeline by Biogen Idec Inc., H1 2015 44
Pulmonary Fibrosis - Pipeline by BiOrion Technologies B.V., H1 2015 45
Pulmonary Fibrosis - Pipeline by Boehringer Ingelheim GmbH, H1 2015 46
Pulmonary Fibrosis - Pipeline by Bristol-Myers Squibb Company, H1 2015 47
Pulmonary Fibrosis - Pipeline by Carolus Therapeutics, Inc., H1 2015 48
Pulmonary Fibrosis - Pipeline by Celgene Corporation, H1 2015 49
Pulmonary Fibrosis - Pipeline by Chong Kun Dang Pharmaceutical Corp., H1 2015 50

Explore more reports on Pulmonary therapeutics industry at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/pulmonary-therapeutics .

About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

For the original version on PRWeb visit: http://www.prweb.com/releases/pulmonary-fibrosis/pipeline-review-h1-2015/prweb12467731.htm

Loading...
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...